🟢 Medtronic is trading 7.83% up in pre-market after first-quarter revenue beat and raised FY27 guidance

Medtronic is trading at $97.75 (+7.83%) after reporting $9.8 billion in first-quarter FY27 revenue, exceeding expectations, and raising FY27 guidance.

• Diabetes and Cardiovascular delivered strong growth.
• Management raised organic revenue guidance to 7.25%–7.75% from 6.75%–7.25% and increased its non-GAAP EPS outlook.
• The scheduled September 1 pre-market earnings release supports the move’s timing; broader markets were lower, making company-specific results the dominant catalyst.